Novozymes As B Stock Performance
| NVZMF Stock | USD 54.50 1.29 2.31% |
Novozymes A/S has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.52, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Novozymes A/S's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novozymes A/S is expected to be smaller as well. Novozymes AS B right now secures a risk of 1.8%. Please verify Novozymes AS B downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Novozymes AS B will be following its current price movements.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Novozymes AS B are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak primary indicators, Novozymes A/S may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
| Begin Period Cash Flow | 963 M |
Novozymes |
Novozymes A/S Relative Risk vs. Return Landscape
If you would invest 5,069 in Novozymes AS B on January 18, 2024 and sell it today you would earn a total of 381.00 from holding Novozymes AS B or generate 7.52% return on investment over 90 days. Novozymes AS B is currently producing 0.131% returns and takes up 1.7976% volatility of returns over 90 trading days. Put another way, 15% of traded pink sheets are less volatile than Novozymes, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Novozymes A/S Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novozymes A/S's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Novozymes AS B, and traders can use it to determine the average amount a Novozymes A/S's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0729
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | NVZMF | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.8 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Novozymes A/S is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novozymes A/S by adding it to a well-diversified portfolio.
Novozymes A/S Fundamentals Growth
Novozymes Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Novozymes A/S, and Novozymes A/S fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novozymes Pink Sheet performance.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X | |||
| Price To Sales | 0.82 X | |||
| Revenue | 17.55 B | |||
| EBITDA | 6.12 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
About Novozymes A/S Performance
To evaluate Novozymes AS B Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Novozymes A/S generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Novozymes Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Novozymes AS B market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Novozymes's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.Things to note about Novozymes AS B performance evaluation
Checking the ongoing alerts about Novozymes A/S for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Novozymes AS B help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Novozymes A/S's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Novozymes A/S's pink sheet performance include:- Analyzing Novozymes A/S's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novozymes A/S's stock is overvalued or undervalued compared to its peers.
- Examining Novozymes A/S's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novozymes A/S's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novozymes A/S's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novozymes A/S's pink sheet. These opinions can provide insight into Novozymes A/S's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes A/S's price analysis, check to measure Novozymes A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes A/S is operating at the current time. Most of Novozymes A/S's value examination focuses on studying past and present price action to predict the probability of Novozymes A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes A/S's price. Additionally, you may evaluate how the addition of Novozymes A/S to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |